Literature DB >> 33496756

CAR T cells better than BiTEs.

John C Molina1,2, Nirali N Shah1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33496756      PMCID: PMC7839358          DOI: 10.1182/bloodadvances.2020003554

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  45 in total

1.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 2.  Recent Advances in Managing Acute Lymphoblastic Leukemia.

Authors:  Daniel J DeAngelo; Elias Jabbour; Anjali Advani
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-05

3.  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Authors:  Mazyar Shadman; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Filippo Milano; Ang Li; Alexandre V Hirayama; Mohamed L Sorror; Sindhu Cherian; Xueyan Chen; Ryan D Cassaday; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; David G Maloney; Cameron J Turtle
Journal:  Blood Adv       Date:  2019-10-22

4.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Authors:  Max S Topp; Nicola Gökbuget; Anthony S Stein; Gerhard Zugmaier; Susan O'Brien; Ralf C Bargou; Hervé Dombret; Adele K Fielding; Leonard Heffner; Richard A Larson; Svenja Neumann; Robin Foà; Mark Litzow; Josep-Maria Ribera; Alessandro Rambaldi; Gary Schiller; Monika Brüggemann; Heinz A Horst; Chris Holland; Catherine Jia; Tapan Maniar; Birgit Huber; Dirk Nagorsen; Stephen J Forman; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2014-12-16       Impact factor: 41.316

5.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

6.  FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.

Authors:  Emily Y Jen; Qing Xu; Aaron Schetter; Donna Przepiorka; Yuan Li Shen; Donna Roscoe; Rajeshwari Sridhara; Albert Deisseroth; Reena Philip; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2018-09-25       Impact factor: 12.531

7.  Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.

Authors:  Sara Ghorashian; Anne Marijn Kramer; Shimobi Onuoha; Gary Wright; Jack Bartram; Rachel Richardson; Sarah J Albon; Joan Casanovas-Company; Fernanda Castro; Bilyana Popova; Krystle Villanueva; Jenny Yeung; Winston Vetharoy; Aleks Guvenel; Patrycja A Wawrzyniecka; Leila Mekkaoui; Gordon Weng-Kit Cheung; Danielle Pinner; Jan Chu; Giovanna Lucchini; Juliana Silva; Oana Ciocarlie; Arina Lazareva; Sarah Inglott; Kimberly C Gilmour; Gulrukh Ahsan; Mathieu Ferrari; Somayya Manzoor; Kim Champion; Tony Brooks; Andre Lopes; Allan Hackshaw; Farzin Farzaneh; Robert Chiesa; Kanchan Rao; Denise Bonney; Sujith Samarasinghe; Nicholas Goulden; Ajay Vora; Paul Veys; Rachael Hough; Robert Wynn; Martin A Pule; Persis J Amrolia
Journal:  Nat Med       Date:  2019-09-02       Impact factor: 53.440

8.  Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.

Authors:  Rebecca A Gardner; Francesco Ceppi; Julie Rivers; Colleen Annesley; Corinne Summers; Agne Taraseviciute; Juliane Gust; Kasey J Leger; Katherine Tarlock; Todd M Cooper; Olivia C Finney; Hannah Brakke; Daniel H Li; Julie R Park; Michael C Jensen
Journal:  Blood       Date:  2019-12-12       Impact factor: 25.476

9.  Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Authors:  Marcelo C Pasquini; Zhen-Huan Hu; Kevin Curran; Theodore Laetsch; Frederick Locke; Rayne Rouce; Michael A Pulsipher; Christine L Phillips; Amy Keating; Matthew J Frigault; Dana Salzberg; Samantha Jaglowski; Joshua P Sasine; Joseph Rosenthal; Monalisa Ghosh; Daniel Landsburg; Steven Margossian; Paul L Martin; Manali K Kamdar; Peiman Hematti; Sarah Nikiforow; Cameron Turtle; Miguel-Angel Perales; Patricia Steinert; Mary M Horowitz; Amy Moskop; Lida Pacaud; Lan Yi; Raghav Chawla; Eric Bleickardt; Stephan Grupp
Journal:  Blood Adv       Date:  2020-11-10

Review 10.  Engineering CAR-T Cells for Next-Generation Cancer Therapy.

Authors:  Mihe Hong; Justin D Clubb; Yvonne Y Chen
Journal:  Cancer Cell       Date:  2020-07-30       Impact factor: 31.743

View more
  6 in total

1.  Relapsed disease: off-the-shelf immunotherapies vs customized engineered products.

Authors:  Reem Karmali
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions.

Authors:  Prarthana J Dalal; Nikita P Patel; Matthew J Feinstein; Nausheen Akhter
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 3.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

Review 4.  T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy.

Authors:  Elien De Bousser; Nico Callewaert; Nele Festjens
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

5.  Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies.

Authors:  Ángel Ramírez-Fernández; Óscar Aguilar-Sopeña; Laura Díez-Alonso; Alejandro Segura-Tudela; Carmen Domínguez-Alonso; Pedro Roda-Navarro; Luis Álvarez-Vallina; Belén Blanco
Journal:  Oncoimmunology       Date:  2022-03-23       Impact factor: 8.110

Review 6.  Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.

Authors:  Mariam Elshiaty; Hannah Schindler; Petros Christopoulos
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.